Tolerability and Immunological Effect of Short UpDosing Immunotherapy With 2 Standardized Native Allergen Extracts Derived From the Pollen of Salsola kali and Cupressus arizonica
Salsola kali is one of the main causes of summer pollinosis in countries with dry and temperate climates [1] . The prevalence of pollinosis caused by cypress pollen has been observed to increase simultaneously with the extensive use of cypress trees as ornamental plants and hedges in residential areas. The pollen of Cupressus arizonica is thought to have higher allergenic potential than other species [2] .
Allergen immunotherapy (AIT) is considered the only treatment that ameliorates symptoms, modulates the natural course of the disease, and provides long-lasting effects in patients with IgE-mediated allergic diseases [3, 4] . Subcutaneous immunotherapy (SCIT) has been widely used and has proven to be efficacious and well-tolerated. It also provides long-term benefit to patients with allergic rhinitis, conjunctivitis, or asthma [5, 6] .
Two new SCIT products containing allergenic pollen extracts of S kali (AVANZ Salsola) and C arizonica (AVANZ Cupressus) have been developed based on previous SCIT products. We present the results of 2 open-label, single-arm, phase II, national (Spain), multicenter clinical trials (EudraCT No.: 2013-001728-20 and 2013-004720-11). Adults with a clinically relevant history of allergic rhinoconjunctivitis with(out) asthma caused by sensitization to pollen of S kali or C arizonica (mean age, 36 and 41 years, respectively) and who had not received AIT with the corresponding allergen extracts in the previous 5 years or concomitantly with any other allergen extract received a 6-week course of SCIT (5 weekly updosing injections and a maintenance dose 2 weeks later). The primary endpoint for both studies was the percentage of patients experiencing at least an adverse drug reaction (ADR). An ADR was defined as any noxious and unintended response to any dose of the investigational medicinal product (primary objective) based on a 30-minute observation period after dosing, subsequent telephone interview, and examination of patients' diaries. ADRs were classified as immediate (within 30 minutes after the injection), delayed (>30 minutes after the injection), local (reactions occurring at the injection site), or systemic (generalized signs/symptoms occurring away from the injection site). All local reactions were recorded, regardless of size. Systemic reactions were graded 0-IV by the investigator according to EAACI guidelines [7] . The secondary objective in both studies was to assess changes in specific IgG4 and IgE levels, which, in immediate skin reactivity, were evaluated before the first SCIT injection and 6 weeks later. The change in the immediate skin response (after 15 minutes) was measured by means of skin prick tests using 3×5-fold concentrations of S kali and C arizonica allergen extracts and with histamine and saline solution as positive and negative controls. The parallel-line assay was used to estimate changes in the skin response, which were expressed by the cutaneous tolerance index (CTI).
According to the primary endpoint for both studies, 69% of patients treated with S kali and 77% of those treated with C arizonica reported at least 1 ADR. With S kali SCIT (51 patients), 97 ADRs were reported. These were all nonserious, with 93 that were mild in intensity, 87 that were local (62.7%), 9 systemic (13.7%), and 1 nonspecific (Table) . With C arizonica SCIT (52 patients), 111 ADRs were reported. These were all nonserious, with 104 that were mild in intensity, 96 that were local (71.2%), 7 systemic (9.6%), and 8 nonspecific (Table) 
01).
It is encouraging to find that no moderate or severe systemic reactions were reported and that all systemic reactions found during the studies were mild in intensity (grade I, EAACI classification), and no measures had to be implemented. The number and nature of the ADRs were overall as expected; all reactions occurred at all dosing steps and were mild in severity, with a higher proportion of local reactions (89.7% with S kali and 86.5% with C arizonica), which resolved completely at the end of the studies. One patient, who was receiving SCIT with C arizonica, experienced a severe adverse event (injection site reaction) that led to discontinuation, although the patient recovered fully. As for S kali, another patient discontinued the trial because of a severe adverse event (ulcerative colitis) that was considered unlikely to be related to the investigational medicinal product.
Findings from the clinical trial reported by Moreno et al [8] , which included 93 patients who received the same SCIT formulation containing Olea europaea-derived pollen, showed similar results to those in the present studies, in terms of number and nature of ADRs. A lower number of participants reported ADRs, although we found that these were generally mild in intensity, occurred across all dosing steps, and were mostly related to the injection site. In a similar open-label clinical trial conducted by Tabar et al [9] (102 patients) to examine the tolerability profile of the 5-week updosing schedule of a SCIT formulation with house dust mite-derived allergen extracts, around half of the study participants reported at least 1 of the 117 ADRs recorded during the trial. Approximately 5% of the affected participants reported mild, grade I systemic reactions, and 47% of the participants reported at least a local reaction that resolved fully before completion of the study.
The induction of specific IgE and IgG4 antibodies is consistent with previous findings for AIT with other allergen extracts [8, 9] . Additionally, the significant reduction in the immediate skin response seen with C arizonica is similar to that observed with mites and olive SCIT [8, 9] .
In conclusion, these 2 new SCIT products derived from S kali and C arizonica administered in a 4-week updosing schedule were well tolerated and induced an early and significant immunological effect.
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